You are logged on as Guest.
RegisterLoginShopping cart (Empty)
 United States
Change country
Home
Products & Services
New Products
Literature
Support
Contact Us
About

Arvanil

Activator of CB1 receptor and TRPV1
 
BML-VR101-0005 5 mg 59.00 USD
 
BML-VR101-0025 25 mg 239.00 USD
 
Replaces Prod. #: ALX-340-042

"Hybrid" activator of CB1 receptor (CB1: Ki=0.5µM; CB2: Ki=>15µM) and TRPV1 (Ki=0.3µM). Also inhibits anandamide uptake (IC50=3.6µM) and fatty acid amide hydrolase (FAAH) (IC50=3µM). A vanilloid analog which is 100-fold more potent than anandamide in producing hypothermia, catalepsy and inhibiting spontaneous activity when administered to mice. Analgesic, vasodilatatory and anti-inflammatory in vivo. Apoptosis inducer.

Product Specification

Alternative Name:N-[(4-Hydroxy-3-methoxyphenyl)methyl]-5Z,8Z,11Z,14Z-eicosatetraenamide, N-Vanillylarachidonamide
 
Formula:C28H41NO3
 
MW:439.6
 
Purity:≥98% (TLC)
 
Appearance:Pale yellow oil.
 
CAS:128007-31-8
 
Solubility:Soluble in DMSO (40mg/ml) or ethanol (20mg/ml).
 
Long Term Storage:Ambient
 
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at room temperature. Stock solutions are stable for up to 3 months at -20°C when stored under an atmosphere of argon or nitrogen.
 
Handling:Keep under inert gas.
Protect from light and oxygen.
 
Background / Technical Information:Please click here for the comprehensive product datasheet.
 
ALX-340-042
Please mouse over
ALX-340-042

Product Literature References

Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis: A.M. Malfitano, et al.; J. Neuroimmunol. 171, 110 (2006), Abstract;
Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease: E. de Lago, et al.; Brain Res. 1050, 210 (2005), Abstract;
Evidence against the presence of an anandamide transporter: S.T. Glaser, et al.; PNAS 100, 4269 (2003), Abstract;
The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway: R. Sancho, et al.; Br. J. Pharmacol. 140, 1035 (2003), Abstract;
A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid: V. Di Marzo, et al.; J. Pharmacol. Exp. Ther. 300, 984 (2002), Abstract;
Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide: V. Di Marzo, et al.; Eur. J. Pharmacol. 406, 363 (2000), Abstract;
Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity: L. De Petrocellis et al.; FEBS Lett. 483, 52 (2000), Abstract;
Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors: D. Melck, et al.; BBRC 262, 275 (1999), Abstract;
another CS2 website
©2010 Enzo Life Sciences, Inc.,